Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 183750 plus Carboplatin-Paclitaxel in Stage IV NSCLC
NCT01234038Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- Oct 2012
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
A Phase 2 trial of LY2275796 in non-small cell lung cancer (NSCLC), sponsored by Ionis Pharmaceuticals. Started Nov 2010; status: completed.
02
Drugs
LY2275796
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01234038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234038.